menu
close_24px

Investor Information

Hemostemix Inc. is a clinical-stage regenerative medicine company advancing autologous cell therapy programs for vascular and ischemic disease.

TSXV: HEM
 OTCQB: HMTXF
 FSE: 2VF0

 

 Market Context and Addressable Opportunity 

Advanced ischemic disease represents a significant global clinical and economic burden.

Chronic limb threatening ischemia and ischemic heart disease are associated with high morbidity, progressive vascular impairment, and substantial long-term management costs across healthcare systems.

Independent market analyses have identified multi-billion-dollar annual market values in these categories, reflecting the scale of advanced ischemic disease management worldwide.

Comp-1

These figures reflect current global market assessments for advanced ischemic and cardiovascular disease treatment markets. They are provided for context and do not represent projected financial performance. 

Clinical-Stage Regenerative Medicine Platform

Hemostemix is a clinical-stage biotechnology company advancing ACP-01, an investigational autologous angiogenic cell therapy derived from a patient’s own blood and evaluated in structured clinical research across multiple ischemic indications.
 
The company’s development strategy is focused on disciplined clinical progression, intellectual property protection, and scalable processing infrastructure.
 
Key Elements of the Platform:
 
• 11 peer-reviewed publications supporting clinical investigation
• Phase I and Phase II clinical studies completed in select indications
• 90+ patents protecting platform technology
• Multi-indication development strategy targeting vascular and ischemic disease
• Structured manufacturing and quality control processes 
 
 ACP-01 remains investigational in all indications and continues to be evaluated through defined clinical programs. 
Autologous stem cell regenerative medicine platform

Clinical-Stage Regenerative Medicine Platform

Hemostemix is a clinical-stage biotechnology company advancing ACP-01, an investigational autologous angiogenic cell therapy derived from a patient’s own blood and evaluated in structured clinical research across multiple ischemic indications.
 
The company’s development strategy is focused on disciplined clinical progression, intellectual property protection, and scalable processing infrastructure.
 
Key Elements of the Platform:
 
  • 11 peer-reviewed publications supporting clinical investigation
  • Phase I and Phase II clinical studies completed in select indications
  • 90+ patents protecting platform technology
  • Multi-indication development strategy targeting vascular and ischemic disease
  • Structured manufacturing and quality control processes 
 
 ACP-01 remains investigational in all indications and continues to be evaluated through defined clinical programs. 
Autologous stem cell regenerative medicine platform

Clinical Development Pipeline

Hemostemix is advancing ACP-01 through structured clinical development across multiple ischemic indications.
 
The company’s development strategy focuses on progressive clinical validation within defined patient populations while expanding into additional vascular disease categories supported by mechanistic rationale and prior study data.
 
Current and investigational indications include:
 

• Peripheral Arterial Disease
• Chronic Limb Threatening Ischemia
• Ischemic Cardiomyopathy
• Vascular Dementia 

hemostemix

 ACP-01 remains investigational in all indications and continues to be evaluated through structured clinical programs. 

Clinical Development Pipeline

Hemostemix is advancing ACP-01 through structured clinical development across multiple ischemic indications.
 
The company’s development strategy focuses on progressive clinical validation within defined patient populations while expanding into additional vascular disease categories supported by mechanistic rationale and prior study data.
 
Current and investigational indications include:
 
  • Peripheral Arterial Disease
  • Chronic Limb Threatening Ischemia
  • Ischemic Cardiomyopathy
  • Vascular Dementia
 

 

hemostemix

 ACP-01 remains investigational in all indications and continues to be evaluated through structured clinical programs. 

 Clinical and Corporate Milestones 

For more than two decades, Hemostemix has advanced ACP-01 through defined clinical investigations, intellectual property development, and operational infrastructure milestones.

The timeline below highlights selected clinical, regulatory, and corporate developments since the company’s founding.

 ACP-01 remains investigational in all indications and continues to be evaluated through structured clinical programs. 

final-3

All milestones reflect historical corporate and clinical events. Inclusion does not imply regulatory approval or commercialization status. 

All milestones reflect historical corporate and clinical events. Inclusion does not imply regulatory approval or commercialization status. 

 Manufacturing and Operational Infrastructure 

 Hemostemix has structured its clinical development strategy to align investigational progress with scalable cell processing, quality control, and operational readiness. 

 ACP-01 remains investigational in all indications and continues to be evaluated through structured clinical programs. 

All milestones reflect historical corporate and clinical events. Inclusion does not imply regulatory approval or commercialization status. 

All milestones reflect historical corporate and clinical events. Inclusion does not imply regulatory approval or commercialization status. 

final-4
The development pathway outlined above reflects Hemostemix’s structured approach to aligning clinical investigation, manufacturing standardization, and operational scalability.
 
Each stage remains subject to regulatory oversight and jurisdictional requirements. ACP-01 remains investigational in all indications.

 Why Hemostemix 

Hemostemix is advancing a disciplined clinical-stage regenerative medicine platform supported by published research, protected intellectual property, and structured operational development.

Key Differentiators:

Clinical-Stage Validation
Phase I and Phase II investigations with peer-reviewed publications supporting investigational findings.

Autologous Angiogenic Cell Platform
ACP-01 is derived from a patient’s own blood and designed to support angiogenic pathways in ischemic disease.

 Intellectual Property Protection
More than 90 patents supporting platform technology and process development. 

Structured Manufacturing Pathway
Defined cell processing protocols and manufacturing agreements designed to support reproducibility and quality control.

Multi-Indication Strategy
Development focus across peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, and vascular dementia.

ACP-01 remains investigational in all indications and continues to be evaluated in structured clinical programs.

 Capital Structure and Corporate Information 

 Hemostemix Inc. is a publicly traded clinical-stage biotechnology company. 

 Ticker Symbols:
TSXV: HEM
OTCQB: HMTXF
FSE: 2VF0 

The company maintains regulatory filings and public disclosures in accordance with applicable exchange requirements.

Investors may access:

• Financial statements
• Management discussion and analysis
• Corporate governance documentation
• Press releases and material updates 

 Capital Structure and Corporate Information 

 Hemostemix Inc. is a publicly traded clinical-stage biotechnology company. 

 Ticker Symbols:
TSXV: HEM
OTCQB: HMTXF
FSE: 2VF0 

The company maintains regulatory filings and public disclosures in accordance with applicable exchange requirements.

Investors may access:

  • Financial statement

  • Management discussion and analysis

  • Corporate governance documentation

  • Press releases and material updates 

 Contact Investor Relations

 For institutional inquiries, partnership discussions, or investor communications, please contact:

Annual General Meeting Materials

 Annual General Meeting Materials 

2025

2024

2023

2022

2025

 

2024

 

2023

 

2022

Disclaimer

IMPORTANT NOTICE
ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration. Information provided on this website is for educational purposes only and does not constitute medical advice. Nothing on this site is intended to promote or market an unapproved therapy. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.
 
FLORIDA NOTICE
This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.